Use your antibodies-online credentials, if available.
Overexpression of NRP2 is associated with spitzoid melanocytic lesions.
The results of this study showed that there is a significant association betweenNPR2 rs849563 polymorphism and autism in the studied population
The authors also identified single-nucleotide polymorphisms in NRP2 and IGFBP4 loci that increase and reduce risk of lichen planus in hepatitis C virus-infected patients, respectively.
Authors found that NRP2 gene silencing in metastatic melanoma cell lines inhibited tumor cell growth in vitro; furthermore, knockdown of NRP2 expression in the metastatic melanoma cell line 1205Lu significantly inhibited in-vivo tumor growth and metastasis.
Study identifies NRP2 and ESL-1 as targets for polysialylation in murine microglia and human THP-1 macrophages and reveals a striking convergence in the regulation of the two polysialylated acceptors in the course of inflammatory activation. A pool of polysialylated NRP2 and ESL-1 is assembled after injury or in culture and its shedding is an early response to lipopolysaccharide-induced activation of microglia.
Neuropilin 2 isoform NRP2b contributed to the oncogenic response to transforming growth factor-beta (TGFbeta) and correlated with tumor progression in non-small cell lung cancer (NSCLC) patients.
Sema3a-Nrp2 signaling along an unrecognized pancreatic developmental axis constitutes a chemoattractant system essential for generating the hallmark morphogenetic properties of pancreatic islets.
NRP2 promotes tumourigenesis and metastasis in Oesophageal squamous cell carcinoma (ESCC) through deregulation of ERK-MAPK-ETV4-MMP-E-cadherin signalling.
The summarizes the structure and function features of pathway-related molecules of VEGFC/D-VEGFR3/NRP2 axis, stages of various tumors and their molecular mechanisms and significances in tuthe expression changes of these molecules in different anatomic organs or histopathologic types or development lymphatic metastasis.
NRP2 inhibits WDFY1 transcription by preventing the nuclear localization of a transcription factor, Fetal ALZ50-reactive clone 1 (FAC1).
Sequence Requirements for Neuropilin-2 Recognition by ST8SiaIV and Polysialylation of Its O-Glycans.
the concurrent high expression of VEGF-C and NRP2 is predictive of the unfavorable prognosis in glioblastoma.
SEMA3F-NRP2 interactions inhibit intracellular PI-3K activity, mTORC2-dependent signaling, RhoA activity and cytoskeletal stress fiber formation.
NRP2/WDFY1 axis is required for maintaining endocytic activity in cancer cells, which supports their oncogenic activities and confers drug resistance.
Data show significant increases in semaphorin3C, 3D and their receptor neuropilin-2 in degenerate samples which were shown to contain nerves and blood vessels, compared to non-degenerate samples without nerves and blood vessels.
the novel interplay between PAX8 and Neuropilin-2
This is the first study in the literature showing that neuropilin-2 and ezrin are related with prognosis in patients with advanced renal cell carcinoma.
Neuropilin-2 expression is inhibited by secreted Wnt antagonists and its down-regulation is associated with reduced tumor growth and metastasis in osteosarcoma
Data indicate that semaphorin 3F (SEMA3F) and its receptor neuropilin-2 (NRP2) are expressed in the thymus.
This is the first report of a targeted MRI molecular probe based on USPIO and VEGF165-aptamer.
This gene encodes a member of the neuropilin family of receptor proteins. The encoded transmembrane protein binds to SEMA3C protein sema domain, immunoglobulin domain (Ig), short basic domain, secreted, (semaphorin) 3C and SEMA3F protein sema domain, immunoglobulin domain (Ig), short basic domain, secreted, (semaphorin) 3F, and interacts with vascular endothelial growth factor (VEGF). This protein may play a role in cardiovascular development, axon guidance, and tumorigenesis. Multiple transcript variants encoding distinct isoforms have been identified for this gene.
, receptor for VEGF165 and semaphorins class3
, vascular endothelial cell growth factor 165 receptor 2